Lipid bilayer-based biological nanoplatforms for sonodynamic cancer therapy

Songhao Li1, Greta S P Mok2, Yunlu Dai1

  • 1Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China; MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR 999078, China.

PubMed

Insights

Lipid bilayer-based nanovesicles enhance sonodynamic therapy (SDT) for cancer by improving sonosensitizer delivery and overcoming tumor microenvironment barriers. This approach offers a promising strategy for next-generation cancer treatments.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Sonodynamic therapy (SDT) shows promise for cancer treatment but faces limitations due to poor sonosensitizer performance and the tumor microenvironment (TME).
  • Lipid bilayer-based nanovesicles (LBBNs) offer a novel platform to address these challenges.

Purpose of the Study:

  • To review recent advances in LBBN-based SDT for cancer therapy.
  • To highlight how LBBNs can improve sonosensitizer delivery and overcome TME barriers.

Main Methods:

  • Comprehensive literature review of LBBN applications in SDT.
  • Analysis of LBBN engineering strategies for enhanced sonosensitizer delivery.
  • Evaluation of LBBNs in overcoming physical, biological, and immune barriers within the TME.

Main Results:

  • LBBNs, including liposomes, exosomes, and cellular membranes, can be functionalized as effective nanocarriers for SDT.
  • Engineered LBBNs improve sonosensitizer delivery efficiency and penetration into the TME.
  • LBBNs help overcome physical, biological, and immune resistance within the TME, enhancing antitumor efficacy.

Conclusions:

  • LBBNs represent a significant advancement in SDT, offering a versatile platform for targeted cancer therapy.
  • Further development of LBBN-based nanosonosensitizers is crucial for next-generation sonodynamic cancer treatments.

Related Concept Videos